Found: 3
Select item for more details and to access through your institution.
FDA Approval Summary: Nivolumab Plus Ipilimumab for the Treatment of Patients with Hepatocellular Carcinoma Previously Treated with Sorafenib.
- Published in:
- Oncologist, 2021, v. 26, n. 9, p. 797, doi. 10.1002/onco.13819
- By:
- Publication type:
- Article
Benefit–Risk Summary of Nivolumab for the Treatment of Patients with Unresectable Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma After Prior Fluoropyrimidine‐ and Platinum‐Based Chemotherapy.
- Published in:
- Oncologist, 2021, v. 26, n. 4, p. 318, doi. 10.1002/onco.13646
- By:
- Publication type:
- Article
A Size-Selective Intracellular Delivery Platform.
- Published in:
- Small, 2016, v. 12, n. 42, p. 5873, doi. 10.1002/smll.201601155
- By:
- Publication type:
- Article